局限期小细胞肺癌胸部放疗剂量分割现状

Thoracic radiotherapy of limited-stage small cell lung cancer:current situation of dose fractionation

胸部放疗是局限期小细胞肺癌的重要治疗手段,与之相关的剂量分割存在一定争议。超分割放疗方案(2次/d)作为前瞻性研究确立的标准方案,由于不良反应的发生和治疗的不便利,在临床实践中常常被其他治疗策略代替。另外在不可手术的淋巴结阴性的Ⅰ期小细胞肺癌中,立体定向消融放疗为部分高龄且预计难以耐受长疗程放疗的患者提供了新的选择。合适的剂量分割方案既可以保证治疗疗效,也能降低放疗相关急性及晚期损伤。本文将对目前局限期小细胞肺癌剂量分割研究现状进行阐述。

Thoracic radiotherapy is a major treatment and dose fractionation remains controversial in limited-stage small cell lung cancer.Twice-daily(BID)radiotherapy,as a standard protocol established in prospective studies,is often replaced by other treatment strategies in clinical practice due to the occurrence of side effects and inconvenience.In addition,in inoperable stageⅠsmall cell lung cancer with negative lymph nodes,stereotactic ablative radiotherapy(SABR)provides a new option for some elderly patients who are expected to be unable to tolerate long-term radiotherapy.The appropriate dose fractionation scheme can both ensure the therapeutic effects and reduce toxic effects.This article reviews the research of limited-stage small cell lung cancer about dose fractionation.